Compare · COO vs RXST
COO vs RXST
Side-by-side comparison of The Cooper Companies Inc. (COO) and RxSight Inc. (RXST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COO and RXST operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- COO is the larger of the two at $19.03B, about 96.0x RXST ($198.3M).
- Over the past year, COO is down 10.6% and RXST is down 68.7% - COO leads by 58.2 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- The Cooper Companies Inc.
- RxSight Inc.
- Price
- $60.31+1.44%
- $4.77-3.25%
- Market cap
- $19.03B
- $198.3M
- 1M return
- -1.92%
- -35.37%
- 1Y return
- -10.55%
- -68.73%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 25
The Cooper Companies Inc.
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
RxSight Inc.
RxSight, Inc., a medical technology company, develops light adjustable lens (LAL) to improve uncorrected visual acuity that can be adjusted enhance uncorrected visual acuity after cataract surgery. It also offers RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is based in Aliso Viejo, California.
Latest COO
- SEC Form SD filed by The Cooper Companies Inc.
- CooperVision Names Muru Annamalai as President, Asia-Pacific
- The Cooper Companies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- CooperCompanies Appoints Paul Keel to its Board of Directors
- CooperCompanies Announces Release Date for Second Quarter 2026
- SEC Form 4 filed by Rosebrough Walter M Jr
- CooperVision Partners with Canadian Olympic Speed Skater Valérie Maltais on Her Continued Pursuit of Excellence on the World Stage
- CooperVision Launches MADE BETTER™ Promise Beginning with MyDay® Contact Lenses*¹
- Telix Strengthens Board with Additional Director Appointments
- The Cooper Companies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest RXST
- SEC Form SD filed by RxSight Inc.
- RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
- SEC Form 10-Q filed by RxSight Inc.
- RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
- RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RxSight, Inc. to Present at the Bank of America Healthcare Conference
- SEC Form DEFA14A filed by RxSight Inc.
- SEC Form DEF 14A filed by RxSight Inc.
- RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
- SEC Form 4 filed by Goldshleger Ilya